REJECTED PRODUCT. Customer must segregate and must not use any Product for any human clinical testing or trials or any other purpose (other than compliance testing pursuant to this Section 6) after it becomes aware of a basis for rejection or a Defect Notice. On a final determination that any Product is Defective, Customer must either (a) return all remaining Product to CMC, or (b) destroy all remaining Product, in either case, at CMC’s election and as soon as possible after request by CMC.
Appears in 2 contracts
Samples: Development and Manufacturing Services Agreement (Harpoon Therapeutics, Inc.), Development and Manufacturing Services Agreement (CytoDyn Inc.)
REJECTED PRODUCT. Customer must segregate and must not use any Product for any human clinical testing or trials or any other purpose (other than compliance testing pursuant to this Section 6) after it becomes aware of a basis for rejection or a Defect Noticerelating to such Product. On a final determination that any Product is DefectiveDefective as a result of CMC’s Fault, Customer must either (a) return [* * *] all remaining Product to CMC, or (b) destroy all remaining Product, in either case, at CMC’s election and as soon as possible after request by CMCelection.
Appears in 1 contract
Samples: Development and Manufacturing Services Agreement (Catalyst Biosciences, Inc.)
REJECTED PRODUCT. Customer must segregate and must not use any Product for any human clinical testing or trials or any other purpose (other than compliance testing pursuant to this Section 6) after it becomes aware of a basis for rejection or a Defect Notice. On a final determination that any Product is DefectiveDefective Product, Customer must either (a) return all remaining Defective Product to CMC, or (b) destroy all remaining Defective Product, in either case, at CMC’s election and as soon as possible after request by CMC and at CMC’s cost.
Appears in 1 contract
Samples: Development and Manufacturing Services Agreement (Horizon Therapeutics Public LTD Co)